Clinical Trial Update: Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating adding lonafarnib to standard Paclitaxel/Carboplatin for first-line treatment of epithelial ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Lonafarnib (lonafarnib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AGO Study Group | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED